Financial Performance - The company achieved an operating revenue of RMB 4.066 billion in 2022, representing a year-on-year increase of 7.49%[24]. - The net profit attributable to shareholders was RMB 350.07 million, an increase of 4.77% compared to the previous year[24]. - The net profit after deducting non-recurring gains and losses was RMB 331.44 million, reflecting a growth of 10.32% year-on-year[24]. - The cash flow from operating activities amounted to RMB 258.35 million, up by 10.59% from the previous year[24]. - The total assets of the company reached RMB 6.815 billion at the end of 2022, an increase of 7.09% compared to the end of 2021[24]. - The basic earnings per share were RMB 0.77, a 4.05% increase from the previous year[25]. - The weighted average return on equity was 6.76%, slightly up from 6.73% in 2021[25]. - The company reported a total profit of RMB 366 million for the year, which is an 8.94% increase year-on-year[35]. - The company reported a significant increase in financial income, contributing to a reduction in financial expenses by 206.86%[58]. - The total revenue for the year 2022 reached approximately ¥4.05 billion, with a year-on-year increase of 7.32%[61]. Dividend Policy - The company plans to distribute a cash dividend of 3.35 RMB per 10 shares, totaling approximately 151.68 million RMB based on 452,775,129 shares[5]. - The total cash dividend amount distributed was approximately ¥151.68 million, which represents 43.33% of the net profit attributable to ordinary shareholders[164]. - The company implemented a cash dividend policy, distributing a cash dividend of 3.00 RMB per 10 shares, amounting to a total of 135,850,238.70 RMB, which represents 40.66% of the net profit attributable to shareholders[155][156]. - The company’s profit distribution policy emphasizes stable and continuous cash dividends, with a focus on maintaining a balance between shareholder returns and sustainable development[157][158]. Research and Development - The company is committed to enhancing its product structure through internal R&D and collaborations with external research institutions, focusing on high-margin products[36]. - The company has engaged in research collaborations with multiple prestigious institutions, facilitating new product development[53]. - R&D investment accounted for over 8% of operating revenue, supporting the company's sustainable development[56]. - The company invested CNY 335 million in R&D in 2022, maintaining an R&D expenditure ratio of over 8% of sales revenue[92]. - There are over 100 ongoing R&D projects focusing on complex injectables, controlled-release oral solid formulations, and other therapeutic areas[93]. - The company is actively seeking collaborations for R&D projects under the new MAH policy to enhance its product pipeline[92]. - The company has completed preclinical research for a new drug targeting autoimmune inflammation and an antiviral drug, both of which have applied for Pre-IND[94]. - The company has established R&D subsidiaries in India, Tianjin, and Jinan to enhance innovation and resource sharing[92]. Market Expansion and Sales Strategy - The company continues to focus on market demand and has been enhancing its sales management system and service tools[35]. - In 2022, the company established a nationwide sales network for new and generic drugs, focusing on OTC drugs, special medical foods, and traditional Chinese medicine, creating three new growth points[36]. - The company expanded its sales team and implemented a four-level training program to enhance the quality of its sales personnel, aiming for professional and precise market services[36]. - The sales model includes both direct sales to hospitals and retail pharmacies, as well as distribution through pharmaceutical companies[51]. - The company plans to focus on expanding its market presence and enhancing its product development strategies in the upcoming year[61]. - The company is investing $200 million in research and development for new technologies over the next two years[85]. - Market expansion efforts include entering two new countries, which are expected to generate an additional $50 million in revenue[86]. Corporate Governance - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring effective internal control and protection of shareholder rights[121]. - The board of directors has established four specialized committees to provide scientific and professional opinions for decision-making[122]. - The company has maintained independence from its controlling shareholder, ensuring no adverse impact on its operations[123]. - The company has adhered to information disclosure regulations, ensuring transparency and equal access to information for all shareholders[124]. - The company held multiple shareholder meetings, ensuring compliance with legal requirements and timely disclosure of resolutions[126]. Environmental Management - The company has established an environmental management department to adapt to stringent environmental regulations and improve operational management capabilities[119]. - The company has received various environmental impact approvals for its projects, demonstrating compliance with regulatory requirements[178]. - The company has implemented an environmental self-monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[183]. - The company has committed to continuous improvement in waste management, with all hazardous waste being handled by authorized environmental firms[190]. - The company has installed activated carbon treatment equipment for exhaust emissions, ensuring compliance with environmental standards[176]. Risk Management - The company faces risks related to macroeconomic conditions and policy changes that could impact its operations and profitability[118]. - Fluctuations in raw material prices pose a significant risk to the company's production costs and profit margins, necessitating proactive procurement strategies[118]. - The company faces risks from intensified industry competition, particularly in the generic and innovative drug sectors, and will focus on maintaining competitive advantages[119]. Employee Development - The company conducted over 1,000 training sessions in 2022, with an average of 50 hours of training per employee, significantly enhancing the overall quality of its workforce[153]. - The company has established a comprehensive training management system, focusing on various functional modules including R&D, sales, quality, production, and safety[153]. - The total number of employees in the parent company is 2,905, and the total number of employees in major subsidiaries is 508, resulting in a combined total of 3,413 employees[150].

证券代码：603367 证券简称：辰欣药业 公告编号：2022-075 辰欣药业股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，做好投资者关系管理工作，辰欣药业股 份有限公司（以下简称"公司"）将参加由山东证监局联合山东上市公司协会等 单位举办的"山东辖区上市公司 2022 年度投资者网上集体接待日"活动，现将 有关事项公告如下： 本次投资者网上集体接待日活动将通过网上平台采取网络远程的方式举行， 投资者可以登录全景网"投资者关系互动平台"（http://ir.p5w.net/）参与本 次活动，活动时间为 2022 年 11 月 16 日（星期三）14:00 至 16:00。 届时公司董事长、总经理、财务总监杜振新先生、董事会秘书续新兵先生及 证券部工作人员将通过网络在线交流形式与投资者就公司治理、经营状况等投资 者关注的问题进行沟通，欢迎广大投资者积极参与。 特此公告。 辰欣药业股份有限公司 董事会 202 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：603367 证券简称：辰欣药业 辰欣药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------------|---------------------------|------------------|-------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,863,465,284.79, representing a 1.74% increase compared to ¥1,831,553,935.01 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥184,050,164.85, a slight increase of 0.74% from ¥182,695,680.05 in the previous year[23]. - The net cash flow from operating activities increased significantly by 147.52%, reaching ¥93,521,579.85 compared to ¥37,783,957.82 in the same period last year[23]. - The basic earnings per share for the first half of 2022 was ¥0.41, up 2.50% from ¥0.40 in the same period last year[26]. - The diluted earnings per share also stood at ¥0.41, indicating a 2.50% increase compared to the previous year[26]. - The company reported a net profit after deducting non-recurring gains and losses of ¥171,432,168.78, which is a 1.10% increase from ¥169,574,758.16 in the same period last year[23]. - The company achieved a total operating revenue of 1.86 billion yuan, an increase of 1.74% compared to the same period last year[47]. - The net profit attributable to shareholders reached 184 million yuan, reflecting a growth of 0.74% year-on-year[47]. - The company's total comprehensive income for the first half of 2022 was approximately ¥183.35 million, compared to ¥179.93 million in the same period of 2021, reflecting a growth of 1.9%[168]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,296,285,146.34, a decrease of 1.06% from ¥6,363,715,061.04 at the end of the previous year[26]. - The total assets decreased from ¥6,363,715,061.04 to ¥6,296,285,146.34, a decline of approximately 1.05%[148]. - The total liabilities decreased from ¥1,308,143,576.19 to ¥1,192,495,740.37, representing a decrease of approximately 8.84%[148]. - The company's total assets decreased to CNY 5,767,923,130.55 from CNY 5,891,870,306.75, a decline of about 2.11%[155]. - The total equity attributable to shareholders increased from ¥5,054,821,024.66 to ¥5,103,331,045.57, an increase of about 0.96%[148]. Cash Flow - The company's cash and cash equivalents decreased by 33.66% to 623 million yuan, attributed to increased investment in financial products[50]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of 93.52 million yuan, up 147.52% from the previous year[47]. - The total cash inflow from investment activities was ¥1,182,837,907.03, down from ¥2,227,181,726.63 in the first half of 2021, indicating a decrease of approximately 47%[174]. - Cash flow from financing activities resulted in a net outflow of ¥138,790,098.98, compared to a larger outflow of ¥320,019,779.08 in the same period of 2021[175]. Research and Development - Research and development expenses accounted for over 8% of sales, supporting the company's sustainable development and innovation efforts[41]. - The company's research and development expenses for the first half of 2022 were CNY 150,387,966.56, down from CNY 157,862,143.19 in the previous year, a decrease of approximately 4.73%[155]. - The company’s operational strategies include ongoing investment in research and development for new products and technologies[33]. - The company has established partnerships with several prestigious universities and research institutions to foster innovation and product development[41]. Production and Operations - The company operates in the pharmaceutical manufacturing industry, with a focus on drug production and related services[33]. - The production process adheres to strict quality management standards, ensuring compliance with approved production processes[36]. - The company has made substantial investments in upgrading production equipment to achieve automation and improve efficiency[46]. - The company has a structured production planning process that involves multiple departments to optimize production efficiency[36]. Environmental Compliance - The company is classified as a key pollutant discharge unit and has obtained pollution discharge permits for its two parks[79]. - The company has implemented various pollution control measures, including the installation of activated carbon treatment equipment for exhaust emissions[79]. - The company has completed environmental impact assessments for its GMP technical upgrades in 2003 and 2004[80]. - The company has established an emergency response plan for environmental incidents, registered with the local environmental bureau[102]. Shareholder Information - The company held a temporary shareholders' meeting on February 25, 2022, with 265,991,591 shares represented, accounting for 58.6746% of total shares[68]. - A total of 9 resolutions were passed during the annual shareholders' meeting on May 18, 2022, including the approval of the 2021 annual report and financial budget for 2022[69]. - The company completed the cancellation of 20,000 restricted stocks on April 21, 2022, reducing the total share capital from 453,333,000 shares to 453,313,000 shares[74]. - Major shareholders, including Chenxin Technology Group, have pledged not to reduce their holdings in the company during the lock-up period and for two years thereafter[109]. Risk Management - The company has not disclosed any significant risks that could materially affect its operations during the reporting period[6]. - The company faces industry cyclical risks due to increased competition and fluctuating product demand and prices, which may impact operational plans[56]. - The company is actively monitoring national policy changes in the pharmaceutical sector to mitigate risks associated with regulatory impacts[57].

Financial Performance - The company's operating revenue for Q1 2022 was ¥869,770,720.65, a decrease of 0.45% compared to the same period last year[6] - The net profit attributable to shareholders was ¥96,747,943.51, down 10.99% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,935,465.75, a decline of 12.07% compared to the previous year[6] - Basic and diluted earnings per share were both ¥0.21, reflecting a decrease of 12.50%[9] - Total operating revenue for Q1 2022 was CNY 869,770,720.65, a slight decrease of 0.11% compared to CNY 873,706,286.17 in Q1 2021[30] - Net profit for Q1 2022 was CNY 96,618,150.94, a decrease of 11.1% compared to CNY 108,638,309.59 in Q1 2021[32] - Earnings per share for Q1 2022 was CNY 0.21, down from CNY 0.24 in Q1 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,311,113,641.66, a decrease of 0.83% from the end of the previous year[9] - The total assets of the company were CNY 6.31 billion, slightly down from CNY 6.36 billion, indicating a decrease of approximately 0.8%[26] - Current liabilities totaled CNY 1.07 billion, a decrease from CNY 1.22 billion, representing a decline of about 11.9%[26] - The total liabilities decreased to CNY 1,158,224,628.91 from CNY 1,308,143,576.19 year-over-year[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,903[16] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 36.55% of the shares, with 89,709,609 shares pledged[16] - Total equity attributable to shareholders increased to CNY 5,152,516,195.37 from CNY 5,054,821,024.66 year-over-year[30] Cash Flow - The cash flow from operating activities showed a net increase of 277.85% due to reduced cash payments related to operating activities[15] - Cash flow from financing activities showed a net outflow of -1,148,694.45, compared to -182,776,935.90 in the previous year[40] - The net cash flow from operating activities was 48,644,592.93, a significant improvement compared to the previous year's negative cash flow of -27,351,739.44[38] - The company received 6,613,149.02 in cash related to operating activities, a decrease from 36,077,528.47 in the previous year[38] Current Assets and Inventory - As of March 31, 2022, total current assets amounted to approximately CNY 4.02 billion, a decrease from CNY 4.14 billion as of December 31, 2021, reflecting a decline of about 3.0%[23] - The company's cash and cash equivalents were reported at CNY 794.63 million, down from CNY 938.98 million, indicating a decrease of approximately 15.3% year-over-year[23] - Accounts receivable increased to CNY 615.89 million from CNY 508.21 million, representing a growth of about 21.2%[23] - Inventory levels rose to CNY 605.91 million, compared to CNY 594.65 million, marking an increase of approximately 1.9%[23] Research and Development - Research and development expenses for Q1 2022 were CNY 64,917,148.86, compared to CNY 69,613,602.09 in Q1 2021, reflecting a decrease of 6.1%[32] Financial Expenses - The company reported a financial expense of CNY -7,011,265.62 in Q1 2022, compared to CNY 519,867.38 in Q1 2021, indicating a significant improvement[32] Other Financial Metrics - Cash paid for employee compensation increased to 87,361,363.19 from 78,757,933.00 year-over-year[38] - The cash paid for taxes was 109,746,643.19, slightly down from 113,033,889.22 in the previous year[38] - Cash received from investment income was 7,000,527.80, a decrease from 19,832,795.21 year-over-year[38] - The company experienced a negative impact of -159,584.76 from foreign exchange fluctuations on cash and cash equivalents[40]

Financial Performance - In 2021, the company's operating revenue was CNY 3,782,592,635.09, an increase of 2.95% compared to CNY 3,674,158,475.21 in 2020[30]. - The net profit attributable to shareholders was CNY 334,146,422.91, representing a decrease of 23.85% from CNY 438,784,463.09 in 2020[30]. - The net profit after deducting non-recurring gains and losses was CNY 300,431,707.46, down 26.38% from CNY 408,094,652.08 in 2020[30]. - The net cash flow from operating activities was CNY 233,598,087.93, a significant decline of 45.80% compared to CNY 431,007,158.05 in 2020[30]. - The total assets at the end of 2021 were CNY 6,363,715,061.04, an increase of 3.21% from CNY 6,165,710,473.50 at the end of 2020[30]. - The basic earnings per share were CNY 0.74, down 23.71% from CNY 0.97 in 2020[30]. - The weighted average return on equity decreased to 6.73%, down 2.52 percentage points from 9.25% in 2020[30]. - The total profit for 2021 was 336.13 million yuan, a decrease of 30.63% compared to the previous year[44]. - The net profit for 2021 was 333.90 million yuan, down 23.66% year-on-year[44]. - The company's equity attributable to the parent company increased by 5.29% to 5.05482 billion yuan, mainly due to an increase in undistributed profits[44]. Research and Development - The company maintained a research and development investment ratio of over 8% of sales revenue, supporting its transformation and sustainable development[47]. - The company has over 400 drug approval numbers, covering various forms including injections and oral solid preparations, which provides a competitive product structure advantage[69]. - Research and development expenses increased by 8.00% to RMB 334,345.85 million, reflecting the company's commitment to innovation[72]. - The company has several projects in the pipeline, including drugs for diabetes and cardiovascular diseases, with some in the middle trial stage[130]. - The company is actively pursuing research and development for new drug formulations to enhance therapeutic efficacy[101]. - The company has received approvals for 3 generic drugs and 4 products through consistency evaluation during the reporting period[124]. - The company is collaborating with CROs to expand its R&D capabilities under the MAH policy, aiming for more product launches[119]. - The company is actively developing new drugs targeting major clinical needs, including anti-tumor and anti-drug-resistant infections[121]. Governance and Compliance - The company maintained a governance structure that complies with relevant laws and regulations, ensuring effective operation and protection of shareholder rights[167]. - The board of directors established four specialized committees, enhancing decision-making quality and governance standards[168]. - The company has implemented strict insider information management practices, preventing any incidents of insider trading or information leaks during the reporting period[171]. - The management team has been proactive in compliance training and financial oversight, enhancing operational control and accountability[170]. - The company has ensured transparency in information disclosure, adhering to regulations and providing equal access to all shareholders[171]. Market Strategy and Expansion - The company expanded its sales network across the country, focusing on OTC drugs, special medical foods, and traditional Chinese medicine products as new growth points[44]. - The company is focused on optimizing its existing product lines while seeking new profit growth points amid significant opportunities and challenges in the pharmaceutical industry[58]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[185]. - A strategic partnership was formed with a leading biotech firm to co-develop innovative therapies, expected to launch in 2024[185]. - The company is actively pursuing market expansion and technological innovation through its various R&D initiatives[151]. Risk Management - The company faces industry cyclical risks due to increased competition and policy changes, necessitating adjustments in production and operational plans[161]. - The company is monitoring national policy changes and adapting internal management to mitigate risks associated with new pharmaceutical regulations[162]. - The company recognizes the high investment and risk associated with drug R&D and is focused on building a high-quality R&D talent team[163]. - The company is aware of market environment risks, including global economic uncertainties, and is adjusting its product structure towards high-tech industries[162]. Compensation and Remuneration - The total pre-tax compensation for the chairman and general manager, Du Zhenxin, was CNY 1.0553 million[177]. - Vice General Manager and Director, Hao Liushan, received CNY 750,200 in pre-tax compensation and held 200,000 shares at year-end due to stock incentive grants[177]. - The total pre-tax compensation for independent director, Sun Xingsheng, was CNY 80,000[177]. - The total pre-tax compensation for independent director, Zhang Hong, was CNY 80,000[177]. - The total pre-tax compensation for independent director, Cai Hong, was CNY 80,000[177].

Financial Performance - The company's revenue for Q3 2021 was ¥925,611,868.13, representing a decrease of 6.72% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥102,805,324.26, down 29.59% year-over-year[7]. - The net profit excluding non-recurring gains and losses was ¥95,104,992.10, reflecting a decline of 34.40% compared to the previous year[7]. - Basic earnings per share for the quarter was ¥0.23, a decrease of 28.13% year-over-year[10]. - Total operating revenue for the first three quarters of 2021 reached ¥2,757,165,803.14, an increase from ¥2,650,423,323.06 in the same period of 2020, representing a growth of approximately 4.03%[27]. - Net profit for the first three quarters of 2021 was ¥285,356,646.18, down from ¥324,268,916.56 in 2020, reflecting a decrease of approximately 12.0%[31]. - The company reported a total comprehensive income of ¥282,770,077.00 for the first three quarters of 2021, down from ¥324,268,916.56 in 2020, reflecting a decline of approximately 12.8%[33]. - Basic earnings per share for the first three quarters of 2021 were ¥0.63, compared to ¥0.72 in the same period of 2020, indicating a decrease of about 12.5%[33]. Assets and Liabilities - Total assets at the end of the quarter were ¥5,930,758,153.06, a decrease of 3.81% from the end of the previous year[10]. - The total assets as of September 30, 2021, are ¥5,930,758,153.06, down from ¥6,165,710,473.50, indicating a decrease of approximately 3.8%[25]. - The total current assets decreased to ¥3,678,286,204.04 from ¥3,950,229,934.55, a decline of about 6.9%[21]. - The total current liabilities decreased to ¥882,860,412.46 from ¥1,284,346,085.73, a reduction of about 31.3%[25]. - The company's long-term liabilities total ¥76,996,973.66, slightly down from ¥79,419,298.50, showing a decrease of about 3.0%[25]. - The total liabilities as of the end of the reporting period were ¥959,857,386.12, down from ¥1,363,765,384.23 in the previous year[27]. - The total equity attributable to shareholders reached ¥4,970,050,015.40, an increase from ¥4,800,949,979.60 in the previous year, representing a growth of approximately 3.5%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥34,523,486.64, down 88.94% compared to the same period last year[10]. - Cash inflow from operating activities totaled ¥2,489,959,044.60, an increase from ¥2,448,595,895.13 in the same period last year, representing a growth of approximately 1.9%[36]. - Cash outflow from operating activities amounted to ¥2,455,435,557.96, compared to ¥2,136,406,965.28 in the previous year, indicating a rise of about 14.9%[36]. - Net cash flow from operating activities was ¥34,523,486.64, a significant decrease from ¥312,188,929.85 year-over-year[36]. - Cash inflow from investment activities reached ¥3,287,397,033.53, a substantial increase from ¥230,420,786.38 in the prior year[38]. - Net cash flow from investment activities was ¥96,315,512.66, down from ¥134,834,826.39 in the same period last year[38]. - Cash inflow from financing activities totaled ¥138,000,000.00, a decrease from ¥331,201,507.49 year-over-year[38]. - Net cash flow from financing activities was -¥321,274,279.08, compared to a positive cash flow of ¥13,865,098.48 in the previous year[38]. - The ending cash and cash equivalents balance was ¥468,067,499.93, down from ¥821,034,253.90 at the end of the same period last year[38]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,051[15]. - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 165,673,200 shares, accounting for 36.54% of total shares[15]. Inventory and Receivables - The inventory as of September 30, 2021, is ¥646,847,634.97, an increase from ¥572,118,681.59, reflecting an increase of approximately 13%[21]. - The accounts receivable increased to ¥585,265,758.74 from ¥498,901,812.25, representing an increase of about 17.3%[21]. Research and Development - Research and development expenses for the first three quarters of 2021 amounted to ¥246,409,047.63, compared to ¥224,431,128.43 in 2020, showing an increase of about 9.8%[31]. - The company has no significant new product or technology developments reported in the current quarter[19].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,831,553,935.01, representing a 10.46% increase compared to ¥1,658,181,213.32 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥182,695,680.05, a slight increase of 1.69% from ¥179,665,880.84 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥169,574,758.16, which is a 3.72% increase from ¥163,488,505.64 in the same period last year[20]. - The basic earnings per share remained stable at ¥0.40, unchanged from the previous year[22]. - The diluted earnings per share also remained at ¥0.40, consistent with the previous year[22]. - The company achieved a total operating revenue of CNY 1.83 billion in the first half of 2021, an increase of 10.46% compared to the same period last year[38]. - The net profit attributable to shareholders was CNY 183 million, reflecting a year-on-year increase of 1.69%[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 170 million, up by 3.72% year-on-year[38]. - Operating costs rose to CNY 771 million, an increase of 15.60% compared to the previous year[39]. - The company reported a net cash flow from operating activities of CNY 37.78 million, down 57.04% from the previous year[39]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,994,052,203.32, down 2.78% from ¥6,165,710,473.50 at the end of the previous year[22]. - The total assets decreased from RMB 6,165,710,473.50 to RMB 5,994,052,203.32, a decline of approximately 2.77%[145]. - Current assets totaled RMB 3,695,727,658.95, down from RMB 3,950,229,934.55, representing a decrease of about 6.43%[145]. - Total liabilities decreased from RMB 1,363,765,384.23 to RMB 1,126,088,575.98, a reduction of about 17.38%[147]. - The company's equity decreased to CNY 4,542,000,211.65 from CNY 4,567,438,502.53, a decrease of about 0.6%[154]. Cash Flow - The net cash flow from operating activities decreased significantly by 57.04% to ¥37,783,957.82 from ¥87,950,865.39 in the previous year[20]. - Cash and cash equivalents at the end of the period were CNY 358 million, a decrease of 45.86% compared to the previous year[44]. - The total cash inflow from operating activities was ¥1,638,677,222.55, an increase from ¥1,510,547,727.31 in the same period of 2020[169]. - The cash paid for purchasing goods and services was 322,686,157.12 RMB, compared to 300,835,340.46 RMB in the previous year[176]. Research and Development - The company has established advanced R&D centers and partnerships with high-end research institutions, enhancing its capability to develop new products and technologies[33]. - Research and development expenses decreased by 5.14% to CNY 158 million[39]. - Research and development expenses for the first half of 2021 were CNY 157,862,143.19, slightly down from CNY 166,421,126.09 in the previous year, a decrease of approximately 5.1%[158]. Market Position and Products - The company has a diverse product structure with over 400 drug approval numbers, covering various forms including injections, tablets, and capsules, which provides a competitive advantage in the pharmaceutical market[33]. - The pharmaceutical industry in China is expected to exceed ¥5.3 trillion in sales revenue by 2025, indicating significant growth potential for the company[29]. - The company successfully obtained production licenses for energy drinks and special medical foods, laying the foundation for future sales[30]. - The company's product "Esomeprazole Magnesium Enteric-coated Capsules" has been approved for sale in the U.S., marking a significant milestone for its international market entry[30]. Environmental Compliance - The company has installed activated carbon treatment equipment for exhaust emissions from various production processes, ensuring compliance with discharge standards[70]. - The company has a quarterly self-monitoring plan for wastewater, including parameters such as pH, chemical oxygen demand, and total nitrogen[78]. - The actual emissions of VOCs were recorded at 5.91 mg/Nm³, well below the limit of 60 mg/Nm³[85]. - The company has been proactive in environmental protection, with no incidents reported during the reporting period[79]. Shareholder Information - The company has 30,125 ordinary shareholders as of the end of the reporting period[125]. - The largest shareholder, Chenxin Technology Group Co., Ltd., holds 165,673,200 shares, representing 36.54% of the total shares[126]. - A total of 800,000 restricted stock units were granted to executives during the reporting period, with each executive receiving 200,000 shares[136]. Risks and Challenges - The company faces risks in drug research and development, including high investment and long development cycles, which may lead to mismatched returns and potential losses[50]. - The company is at risk of losing core technical personnel, which could adversely affect its profitability[53]. - Environmental risks are present due to the company's status as a key pollutant discharger, necessitating compliance with stricter environmental regulations[53].

2021 年第一季度报告 公司代码：603367 公司简称：辰欣药业 辰欣药业股份有限公司 2021 年第一季度报告 1 / 19 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 19 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人杜振新、主管会计工作负责人杜振新及会计机构负责人（会计主管人员）续新兵 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-------------------------------------------------|--------------- ...

Financial Performance - The company's operating revenue for 2020 was approximately RMB 3.67 billion, a decrease of 10.66% compared to 2019[26]. - Net profit attributable to shareholders for 2020 was approximately RMB 438.78 million, down 14.73% from the previous year[26]. - Basic earnings per share for 2020 were RMB 0.97, reflecting a decrease of 14.91% compared to RMB 1.14 in 2019[30]. - The total assets at the end of 2020 reached approximately RMB 6.17 billion, an increase of 11.42% from 2019[29]. - The company reported a quarterly revenue of RMB 1.02 billion in Q4 2020, showing a steady growth trend throughout the year[32]. - The weighted average return on equity for 2020 was 9.25%, down 2.54 percentage points from 2019[30]. - The net profit after deducting non-recurring gains and losses for 2020 was approximately RMB 408.09 million, a decrease of 14.26% from 2019[26]. - The company achieved a total revenue of 3.674 billion yuan in 2020, a decrease of 10.66% compared to the previous year[62]. - The net profit attributable to shareholders was 439 million yuan, down 14.73% year-on-year[62]. - The revenue from large-volume injection products was 1.861 billion yuan, a decline of 12.75% compared to the previous year[62]. - The revenue from small-volume injection products was 723 million yuan, down 17.67% year-on-year[62]. - The revenue from solid oral preparations was 430 million yuan, a decrease of 2.83% compared to the previous year[62]. - The revenue from drops and ointments increased by 4.67% to 294 million yuan[62]. - The sales of PP ampoule products grew by 14.06%, indicating a positive growth trend and increased market share[62]. Dividend Policy - The company plans to distribute a cash dividend of 2.56 RMB per 10 shares, totaling approximately 115.94 million RMB, based on a total share capital of 45.34 million shares as of December 31, 2020[6]. - The net profit attributable to the parent company for 2019 was 514,580,078 RMB, after deducting statutory reserves and dividends payable[193]. - The company maintains a stable profit distribution policy, prioritizing cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditures[197][200]. - The cash dividend was fully distributed by July 15, 2020[196]. - The company's profit distribution policy allows for cash, stock, or a combination of both, depending on profitability and cash flow conditions[196][200]. - The board of directors is responsible for proposing dividend plans, which must be approved by the shareholders' meeting[197]. - The company emphasizes the protection of minority shareholders' rights in the profit distribution process[197]. - The cash dividend policy stipulates that during growth phases with significant capital expenditures, the minimum cash dividend ratio should be 20%[200]. - The company is committed to ensuring that any non-distribution of cash dividends is transparently disclosed along with the reasons and future plans for retained earnings[200]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has outlined various risks and corresponding mitigation measures in the report, which can be found in the section discussing operational risks[8]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties during the reporting period[8]. - The company has not reported any violations of decision-making procedures regarding external guarantees during the reporting period[8]. - The company acknowledges potential risks from the ongoing COVID-19 pandemic, which may impact sales revenue in 2021[184]. - The company is aware of the risks associated with product quality control and is enhancing its management efforts to mitigate these risks[187]. Audit and Compliance - The audit report issued by Da Xin Certified Public Accountants was a standard unqualified opinion, ensuring the accuracy and completeness of the financial report[5]. - The company’s board of directors and supervisory board members confirmed the authenticity and completeness of the annual report[4]. - The company has implemented a dual prevention system for safety risk control and hazard identification[180]. - The company is actively managing safety production and environmental compliance, aligning with the new national safety production law[180]. Research and Development - The company maintains a research and development investment ratio of over 8% of sales, supporting sustainable development and transformation[48]. - The company invested over 8% of its sales revenue in R&D, supporting its transformation and sustainable development[65]. - The company has over 60 ongoing projects focused on complex injections, specialty drugs, and consistency evaluation of generic drugs[135]. - The company is focusing on developing new drugs for major clinical needs, including treatments for cancer and antibiotic-resistant infections[136]. - The company has several key R&D projects, including a new anti-tumor drug (WXWH0240) in the Pre-IND stage and a new drug for autoimmune inflammation currently in preclinical research[141]. - The company reported a total R&D investment of 128,587,000 RMB, which accounts for 7.29% of its operating revenue and 9.75% of its net assets[149]. - The company is developing a new drug for diabetes treatment (Sitagliptin Phosphate Tablets) which is currently in the supplementary research phase[141]. - The company has received approval for the Esomeprazole Magnesium Enteric-Coated Capsules for treating gastroesophageal reflux disease[144]. - The company is in the process of reviewing the application for Adefovir Dipivoxil Tablets, which is an antiviral drug for hepatitis B[144]. - The company has ongoing projects for innovative formulations of existing drugs, including Ambroxol Hydrochloride Injection and Dexmedetomidine Hydrochloride Injection, both currently under review[146]. - The company’s R&D investment as a percentage of operating revenue is 8.43%, which is above the industry average of 7.14%[149]. - The company has terminated several R&D projects due to market prospects and development progress considerations, including the low molecular heparin characterization project[147]. - The company is focusing on expanding its product pipeline with new drugs targeting various therapeutic areas, including anti-fungal and anti-viral medications[143]. - The company is actively pursuing regulatory approvals for multiple products, indicating a robust pipeline and commitment to innovation[144]. Market Strategy - The company plans to continue expanding its product offerings and market presence in the pharmaceutical sector[40]. - The company has established a comprehensive sales system and market support framework, with offices in major provinces to coordinate drug delivery and customer service[48]. - The company engages in both direct sales to hospitals and retail pharmacies and distribution through pharmaceutical companies, enhancing market reach[47]. - The company is focusing on optimizing product structure and channels to meet customer demands effectively[160]. - The company aims to enhance its market presence by increasing investments in grassroots markets and strengthening local operations[160]. - The company plans to expand its international trade and increase exports to enhance its market reach[160]. - The company is transitioning its sales model from a primarily agency-based approach to a more integrated terminal sales model[160]. - The company plans to enhance R&D efforts, focusing on high-tech and high-difficulty products, ensuring a sustainable development cycle[175]. - The company aims to optimize its sales service system and expand its marketing network to improve new product promotion capabilities[175]. - The company will leverage capital markets for acquisitions to achieve low-cost expansion and cross-industry development[175]. Industry Trends - The pharmaceutical manufacturing industry is experiencing a shift towards innovation and higher clinical value products due to policy changes[104]. - The industry is expected to see intensified competition and structural adjustments driven by government policies and market demands[105]. - The National Medical Products Administration released new regulations to optimize drug registration and approval processes, effective from July 1, 2020[112]. - The ongoing impact of the COVID-19 pandemic has influenced consumer attitudes towards pharmaceutical consumption and accelerated industry transformation[51]. - The total profit for the pharmaceutical manufacturing industry reached 3,506.70 billion CNY in 2020, with a year-on-year increase of 12.8%[51].